Retrospective analysis of a pilot pharmacist-led hospice deprescribing program initiative.


Journal

Journal of the American Geriatrics Society
ISSN: 1532-5415
Titre abrégé: J Am Geriatr Soc
Pays: United States
ID NLM: 7503062

Informations de publication

Date de publication:
05 2021
Historique:
revised: 18 02 2021
received: 18 11 2020
accepted: 23 02 2021
pubmed: 28 3 2021
medline: 29 9 2021
entrez: 27 3 2021
Statut: ppublish

Résumé

Medication deprescribing in palliative care settings has been insufficiently studied. To determine the feasibility of a deprescribing program in hospice patients with limited life expectancy. Pharmacist-led, single arm, single-centered, retrospective analysis of a pilot deprescribing program in an integrated healthcare delivery organization between 9/1/2018 to 1/31/2019. The primary outcome was the proportion of patients who achieved ≥50% reduction of the recommended medications to deprescribe. A total of 97 patients were included in the analysis. The average age was 77.5 ± 23.7 years, with 53.6% being women and 54.6% white. The most common primary diagnosis was cancer (58.8%), with cardiovascular disease the next most common (15.5%). The mean number of baseline comorbidities was 2.0 ± 1.6. Of 698 prescriptions at the start of hospice enrollment, 79.4% of patients achieved a ≥50% reduction in medications recommended for deprescribing. This success was seen mostly in cardiovascular and other nonspecific medications. We found that every 1-unit increase in the number of patient encounters with hospice pharmacists was associated with a 3.2-fold higher odds of achieving a ≥50% reduction in medications that were recommended for deprescribing. The findings from this pilot study revealed that a collaborative, pharmacist-led, collaborative medication deprescribing program initiative was associated with a 79% success in ≥50% medication reduction. More frequent patient encounters had higher odds of success. Future studies, utilizing a control group, should focus on determining the effectiveness of the program and the impact on quality of life.

Identifiants

pubmed: 33772752
doi: 10.1111/jgs.17122
doi:

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1370-1376

Informations de copyright

© 2021 The American Geriatrics Society.

Références

Garber J, Brownlee S. Medication overload: America's other drug problem. Lown Inst. 2019;3-13. https://doi.org/10.46241/LI.WOUK3548.
Krishnaswami A, Steinman MA, Goyal P, et al. Deprescribing in older adults with cardiovascular disease. J Am Coll Cardiol. 2019;73:2584-2595.
Currow DC, Stevenson JP, Abernethy AP, Plummer J, Shelby-James TM. Prescribing in palliative care as death approaches. J Am Geriatr Soc. 2007;55:590-595.
Warraich HJ, Hernandez AF, Allen LA. How medicine has changed the end of life for patients with cardiovascular disease. J Am Coll Cardiol. 2017;70:1276-1289.
McNeil MJ, Kamal AH, Kutner JS, Ritchie CS, Abernethy AP. The burden of polypharmacy in patients near the end of life. J Pain Symptom Manage. 2016;51:178-183.e2.
Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175:827-834.
Paque K, Vander R, Elseviers M, et al. Barriers and enablers to deprescribing in people with a life-limiting disease: a systematic review. Palliat Med. 2019;33(1):37-48.
Hui RL, Chang CC, Niu F, et al. Evaluation of a pharmacist-managed Antidiabetic Deprescribing program in an integrated health care system. J Manag Care Spec Pharm. 2019;25(8):927-934. https://doi.org/10.18553/jmcp.2019.25.8.927.
Kuntz JL, Kouch L, Christian D, Hu W, Peterson PL. Patient education and pharmacist consultation influence on nonbenzodiazepine sedative medication Deprescribing success for older adults. Perm J. 2019;23:18-161. https://doi.org/10.7812/TPP/18-161.
Dharmarajan T, Choi H, Hossain N, et al. Deprescribing as a clinical improvement focus. J Am Med Dir Assoc. 2020;21(3):355-360.
Gulliford M, Ravindrarajah R, Hamada S, Jackson S, Charlton J. Inception and deprescribing of statins in people aged over 80 years: cohort study. Age Ageing. 2017;46(6):1001-1005.
Björnsson E, Abrahamsson H, Simrén M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;24(6):945-954.
Lin R, Sridharan S, Smith L, Young V, Rosen C. Weaning of proton pump inhibitors in patients with suspected laryngopharyngeal reflux disease. Laryngoscope. 2018;128(1):133-137.
Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging. 2008;25:1021-1031.
Kutner JS, Blatchford PJ, Taylor DH Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med. 2015;175:691-700.
Jenner KM, Simmons BJ, Delate T, Clark NP, Kurz D, Witt DM. An education program for patient self-Management of Warfarin. Perm J. 2015;19:33-38.
Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294:716-724.
Goyal P, Anderson TS, Bernacki GM, et al. Physician perspectives on deprescribing cardiovascular medications for older adults. J Am Geriatr Soc. 2019;68(1):78-86.
Mecca MC, Thomas JM, Niehoff KM, et al. Assessing an Interprofessional Polypharmacy and Deprescribing educational intervention for primary care post-graduate trainees: a quantitative and qualitative evaluation. J Gen Intern Med. 2019;34:1220-1227.
Ammerman CA, Simpkins BA, Warman N, Downs TN. Potentially inappropriate medications in older adults: Deprescribing with a clinical pharmacist. J Am Geriatr Soc. 2019;67:115-118.
Lavan AH, Gallagher P, Parsons C, O'Mahony D. STOPPFrail (screening tool of older persons prescriptions in frail adults with limited life expectancy): consensus validation. Age Ageing. 2017;46:600-607.

Auteurs

Vy Le (V)

Division of Pharmacy, Kaiser Permanente San Jose Medical Center, San Jose, California, United States.

Neerali Patel (N)

Division of Pharmacy, Kaiser Permanente San Jose Medical Center, San Jose, California, United States.

Quyen Nguyen (Q)

Division of Pharmacy, Kaiser Permanente San Jose Medical Center, San Jose, California, United States.

Henock Woldu (H)

Division of Pharmacy, Kaiser Permanente San Jose Medical Center, San Jose, California, United States.

Lily Nguyen (L)

Division of Pharmacy, Kaiser Permanente San Jose Medical Center, San Jose, California, United States.

Ava Lee (A)

Division of Hospice and Palliative Care, Kaiser Permanente San Jose Medical Center, San Jose, California, USA.

Lynn Deguzman (L)

Kaiser Permanente, Regional Office, Oakland, California, USA.

Ashok Krishnaswami (A)

Division of Cardiology, Kaiser Permanente San Jose Medical Center, San Jose, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH